What does Phathom Pharmaceuticals, Inc. do?
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related…
What is Phathom Pharmaceuticals, Inc.'s P/E and P/B ratio?
Phathom Pharmaceuticals, Inc. has a P/E ratio of -5.6 and a P/B ratio of -1.65.
What is Phathom Pharmaceuticals, Inc.'s debt-to-equity ratio?
Phathom Pharmaceuticals, Inc. has a debt-to-equity ratio of -0.48.
How much does Phathom Pharmaceuticals, Inc. owe compared with what it owns?
Phathom Pharmaceuticals, Inc. owes $2.05 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Phathom Pharmaceuticals, Inc.'s Positivity rank?
Phathom Pharmaceuticals, Inc. is ranked #6,417 of 6,775 companies globally and #3,679 of 4,000 in United States on PositoAI, with a Positivity Score of -19,041.
Does Phathom Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Phathom Pharmaceuticals, Inc..
Where can I read the latest news about Phathom Pharmaceuticals, Inc.?
Recent headlines about Phathom Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Phathom Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Phathom Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.